The amelioration of hyperlipidemia and decreased body weight after CM treatment (data not presented) were accompanied by a significant decrease (p < 0.0001) in serum leptin and increased (p < 0.0001) circulating adiponectin levels in the NAFLD+CM group in comparison to the NAFLD group. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.